Laboratory Testing for Hepatitis B

Chronic Hepatitis B Therapeutic Options

June 2008

In the United States, currently the therapeutic options that are FDA-approved are shown on this slide. There are two forms of interferon preparations for treating chronic Hepatitis B, and there are three nucleoside analogs, (top 3). The other two agents are actually approved by the FDA for treating HIV infection, but they have been used by hepatologists for treating drug resistant chronic Hepatitis B.

Finally the last class of FDA-approved anti-Hepatitis B viral agent is Adefovir which is a nucleotide analog.

< Previous Slide

Chronic Therapeutic Options

Next Slide >

 

Jump to section:

• Introduction
• Patient Case
• Patient Case
• Acute HBV Infection with Recovery
• Progression to Chronic HBV Infection
• Serologic Markers
• Serologic Methods
• Diagnosis
• Anti-HBs - Qualitative vs Quantitative
• Anti-HBs - Qualitative vs Quantitative
• Molecular Testing
• HBV DNA Quantification Assays
• Patient Case
• Chronic Hepatitis B Therapeutic Options
• Patient Case
• Virologic Breakthrough During Rx for CHB
• HBV Genotyping and Drug Resistance Tests
• HBV Resistance Mutations
• Patient Case
• Summary
• Questions?
• Disclosure